Grant: Operating Grant - Priority Announ - Institute of Human Dev, Child & Youth Health
Research Institute of the McGill University Health Centre
$100,000.00
Improving the quality of oocytes used for in vitro fertilization
EF 2008-09
Résumé
A growing number of Canadian women are turning to in vitro fertilization (IVF) to help them have children. IVF typically requires injections for up to a month of follicle-stimulating hormone (FSH) and other drugs. These are stressful, and the drugs are expensive and may pose health risks to the woman or embryo. Therefore, clinics have begun to introduce a technique termed oocyte maturation in vitro. This technique requires no drugs and thus eliminates the associated stress, cost and health risks. Unfortunately, it is not yet very efficient - the 'take-home' baby rate is only half that of traditional IVF. Improving the quality of in vitro-matured oocytes is essential to enable the benefits of this technique to be realized.
Most efforts to improve oocyte quality have focused on the culture conditions used for maturation. Largely overlooked has been that, although oocytes normally do not undergo maturation until after they have completed the preceding phase of development, termed growth, oocytes used for in vitro maturation are obtained before they have completed growth. Studies using animals have shown that when such precociously matured oocytes are fertilized, they become arrested and die during early embryonic development. We hypothesize that (1) in vitro-matured oocytes develop poorly because they are obtained before they have completed growth; and (2) when oocytes are allowed to complete growth in vitro before undergoing maturation and fertilization, they will develop as healthy embryos.
To test our hypotheses, we will define (1) molecular differences between oocytes that have or have not completed growth; (2) the specific role of FSH in oocyte development; (3) conditions that allow oocytes to complete their growth in vitro so that, following maturation and fertilization, they will give rise to healthy embryos. We expect that the results can be directly translated to the clinic to improve the ability of in vitro-matured oocytes to produce healthy infants.
Programme
Operating Grant - Priority Announ - Institute of Human Dev, Child & Youth Health
Emplacement
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
183215
Name
Clarke Hugh J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Gender, Sex & Health
Projecttitle
Improving the quality of oocytes used for in vitro fertilization
Programtype2
Operating Grants
Orgnameinp2
Research Institute of the McGill University Health Centre
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announ - Institute of Human Dev, Child & Youth Health
Keyworddelim
Assisted Reproduction; Infertility; Oogenesis; Ovary
Abstract
A growing number of Canadian women are turning to in vitro fertilization (IVF) to help them have children. IVF typically requires injections for up to a month of follicle-stimulating hormone (FSH) and other drugs. These are stressful, and the drugs are expensive and may pose health risks to the woman or embryo. Therefore, clinics have begun to introduce a technique termed oocyte maturation in vitro. This technique requires no drugs and thus eliminates the associated stress, cost and health risks. Unfortunately, it is not yet very efficient - the 'take-home' baby rate is only half that of traditional IVF. Improving the quality of in vitro-matured oocytes is essential to enable the benefits of this technique to be realized.
Most efforts to improve oocyte quality have focused on the culture conditions used for maturation. Largely overlooked has been that, although oocytes normally do not undergo maturation until after they have completed the preceding phase of development, termed growth, oocytes used for in vitro maturation are obtained before they have completed growth. Studies using animals have shown that when such precociously matured oocytes are fertilized, they become arrested and die during early embryonic development. We hypothesize that (1) in vitro-matured oocytes develop poorly because they are obtained before they have completed growth; and (2) when oocytes are allowed to complete growth in vitro before undergoing maturation and fertilization, they will develop as healthy embryos.
To test our hypotheses, we will define (1) molecular differences between oocytes that have or have not completed growth; (2) the specific role of FSH in oocyte development; (3) conditions that allow oocytes to complete their growth in vitro so that, following maturation and fertilization, they will give rise to healthy embryos. We expect that the results can be directly translated to the clinic to improve the ability of in vitro-matured oocytes to produce healthy infants.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Clarke, Hugh J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~